Study results disclosed at the American Society of Hematology meeting Saturday suggested potential for cell therapy in lupus and pointed out drug trial limitations.
Follow-up data continue to show Lyfgenia can address the pain crises people with sickle cell experience, although Bluebird’s therapy will be compared to Vertex and CRISPR Therapeutics’ Casgevy, which ...
In addition to clearing Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy, the FDA also granted an early OK to Bluebird bio’s sickle cell treatment Lyfgenia.
Casgevy, the first CRISPR therapy approved by the FDA, will cost $2.2 million, while a competing genetic medicine also cleared Friday is priced at $3.1 million.
The deal hands AbbVie a portfolio of psychiatric medicines that originated within Pfizer, among them a closely watched schizophrenia treatment that’s in late-stage testing.
The White House is supporting a policy that would allow the U.S. government to sidestep patent protections for drugs developed with federal funding and that have prices deemed “extreme, unjustified, ...
Data collected by the research firm suggests venture funding totals are still sliding amid a "strategic shift" by investors towards fewer, but more substantial deals.
The private placement funding will help Spyre develop its drug pipeline, which includes a TL1A-targeting therapy for inflammatory bowel disease.
Mark McDonald, president, WCG Review Solutions, expressed his enthusiasm for the launch, “IRB+ represents a significant leap ...
The pharma is developing Fabhalta, now cleared for paroxysmal nocturnal hemoglobinuria, for several other rare, complement-driven diseases.
Launched from BrainChild founder Michael Jensen’s lab at the Washington-area hospital, the company is focusing first on pediatric brain tumors.
U.S. tax law changes six years ago slashed large pharma companies' rates and saved them billions. Now, a push for an international floor could disrupt their R&D accounting.